Pinnacle Associates’s Bicycle Therapeutics BCYC Stock Holding History

Pinnacle Associates’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$806K	Buy	189,990 +4,580	+2%	+$21K	0.01%	583
2026 Q1	$860K	Sell	185,410 -5,070	-3%	-$29K	0.01%	546
2025 Q4	$1.35M	Sell	190,480 -6,138	-3%	-$45.3K	0.02%	469
2025 Q3	$1.52M	Buy	196,618 +24,665	+14%	+$186K	0.02%	441
2025 Q2	$1.2M	Sell	171,953 -42,325	-20%	-$337K	0.02%	472
2025 Q1	$1.82M	Sell	214,278 -12,464	-5%	-$147K	0.03%	391
2024 Q4	$3.17M	Buy	+226,742	New	+$4.86M	0.04%	303
2024 Q3	–	Sell	-242,001	Closed	-$4.9M	–	806
2024 Q2	$4.9M	Buy	242,001 +161,911	+202%	+$3.66M	0.08%	245
2024 Q1	$1.99M	Buy	+80,090	New	+$1.7M	0.03%	371

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GSK plc London $602M AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Pinnacle Associates's BCYC Position: Q2 2026 in Review

Pinnacle Associates increased its Bicycle Therapeutics (BCYC) stake by 2.5% in Q2 2026, buying an estimated $21K and bringing the position to 189,990 shares worth $806K. The position accounts for 0.01% of the portfolio, ranked #583.

Pinnacle Associates first reported a position in BCYC in Q1 2024 and has held it in 9 quarters since. The position peaked at $4.9M in Q2 2024. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

Pinnacle Associates held 189,990 shares of Bicycle Therapeutics worth $806K as of Q2 2026.
Pinnacle Associates bought 4,580 Bicycle Therapeutics shares in Q2 2026, an estimated $21K.
Bicycle Therapeutics made up 0.01% of Pinnacle Associates's portfolio in Q2 2026, its #583 holding.
Pinnacle Associates first reported a position in Bicycle Therapeutics in Q1 2024 and has held it in 9 quarters since.
Pinnacle Associates's Bicycle Therapeutics position peaked at $4.9M in Q2 2024.
104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Pinnacle Associates's 13F filing for Q2 2026, filed 3 Aug 2026.